Secretase inhibition in Alzheimer’s
disease therapeutics reveals
functional roles of amyloid-beta42
Timothy Daly*
, Bruno P. Imbimbo
UMR 1219 (Bordeaux Population Health)
University of Bordeaux & INSERM, Bordeaux,
France (Daly T)
CNS UMR 5164 (ImmunoConcept), University of
Bordeaux, Bordeaux, France (Daly T)
Bioethics Program, FLACSO Argentina, Tucumán,
Buenos Aires, Argentina (Daly T)
Research & Development, Chiesi Farmaceutici,
Parma, Italy (Imbimbo BP)
Dr. Timothy Daly has no financial relationships or conflicts
of interest to declare. Dr. Bruno P. Imbimbo is an employee
at Chiesi Farmaceutici. He is listed as an inventor in a
number of Chiesi Farmaceutici’s patents of anti-Alzheimer
drugs. No conflicts of interest exist between Chiesi
Farmaceutici and publication of this article.
The words of Sir Colin Blakemore were paraphrased from
a 2014 public lecture he gave at the “Brain Matters” event
at the University of Nottingham, attended by Timothy
Daly (https://www.nottingham.ac.uk/research/groups/
neuroscience/brainmatters/an-evening-with/tickets.
aspx#book)